Translational Metabolomics Shared Resource (TraMSR)

The Translational Metabolomics Shared Resource supports cancer metabolism research, spanning from the analysis of molecules to organelles, to cells and tissues.

Scheduling, Location, and Hours of Operation

Mass Spectrometry: Translational and Biomedical Research Center, 2nd floor
Redox and Bioenergetics: MACC Fund Research Center, 2nd floor
Preclinical and Clinical Imaging: Medical Imaging Research Center, 1st floor
Monday–Friday from 8 a.m.-5 p.m.
Submit a TraMSR iLab request

Services and Technologies

TraMSR provides expertise and services in 1) mass spectrometry (MS) analyses of the tumor metabolome; 2) bioenergetic and redox function analyses; 3) imaging of preclinical models; and 4) quantitative MRI-based clinical response assessments for monitoring patients on clinical trials.  

Mass Spectrometry
  • MS sample preparation
  • MS instrumentation: Bruker timsTOF Flex MALDI imaging; Thermo Exploris 240, Waters XEVO
  • MS-based omics analysis: lipidomics, glycomics, glycoproteomics, metabolomics
Redox and Bioenergetics
  • Redox: ROS measurements; GSH/GSSG measurements; redox immunoblotting
  • Metabolism: metabolic pathway profiling; mitochondrial oxygen consumption; glycolytic function; mitochondrial membrane potential; metabolic reprogramming
  • Instrumentation: Agilent Seahorse extracellular flux analyzers; HPLC and UHPLC systems; electron paramagnetic resonance (EPR) and luminescence spectrometers
Preclinical Imaging
  • IVIS SpectrumCT: small animal bioluminescence and fluorescence, low dose X ray microCT and Cherenkov Luminescence imaging
  • Small animal near-infrared (NIR) and short-wave infrared imaging (SWIR)
Clinical Imaging
  • Patient tumor and lymph node measurements and volumetrics
  • Clinical trial level reporting and audit support
  • Cloud-based image repository and tools



Peter LaViolette, PhD

Director, Translational Metabolomics Shared Resource (TraMSR)

Notable Publications

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. (Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M) Adv Sci (Weinh) 2022 Apr;9(12):e2101267 PMID: 35243806 PMCID: PMC9036031 SCOPUS ID: 2-s2.0-85125564839 03/05/2022

Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. (Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, Bradley WH, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P) Cancer Res 2021 Oct 15;81(20):5336-5352 PMID: 34380633 PMCID: PMC8530981 SCOPUS ID: 2-s2.0-85116424540 8/13/2021

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. (Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, Hainsworth J, Meric-Bernstam F, Swanton C, Sweeney CJ, Friedman CF, Bose R, Spigel DR, Wang Y, Levy J, Schulze K, Cuchelkar V, Patel A, Burris H) Lancet Oncol 2021 Sep;22(9):1290-1300 PMID: 34339623 DOI: 10.1016/S1470-2045(21)00336-3 SCOPUS ID: 2-s2.0-85113412076 8/03/2021

Nuclear PFKP promotes CXCR4-dependent infiltration by T cell acute lymphoblastic leukemia. (Gao X, Qin S, Wu Y, Chu C, Jiang B, Johnson RH, Kuang D, Zhang J, Wang X, Mehta A, Tew KD, Leone GW, Yu XZ, Wang H) J Clin Invest 2021 Aug 16;131(16) PMID: 34255748 PMCID: PMC8363288 SCOPUS ID: 2-s2.0-85113146308 07/14/2021

WDR26 and MTF2 are therapeutic targets in multiple myeloma. (Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S) J Hematol Oncol 2021 Dec 07;14(1):203 PMID: 34876184 PMCID: PMC8650373 SCOPUS ID: 2-s2.0-85120899924 12/09/2021